Unknown

Dataset Information

0

Lenalidomide enhances anti-myeloma cellular immunity.


ABSTRACT: Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to reverse tumor-mediated immune suppression and amplify myeloma-specific immunity is currently being explored. In the present study, we examined the effect of lenalidomide on T-cell activation and its ability to amplify responses to a dendritic cell-based myeloma vaccine. We demonstrate that exposure to lenalidomide in the context of T-cell expansion with direct ligation of CD3/CD28 complex results in polarization toward a Th1 phenotype characterized by increased IFN-?, but not IL-10 expression. In vitro exposure to lenalidomide resulted in decreased levels of regulatory T cells and a decrease in T-cell expression of the inhibitory marker, PD-1. Lenalidomide also enhanced T-cell proliferative responses to allogeneic DCs. Most significantly, lenalidomide treatment potentiated responses to the dendritic cell/myeloma fusion vaccine, which were characterized by increased production of inflammatory cytokines and increased cytotoxic lymphocyte-mediated lysis of autologous myeloma targets. These findings indicate that lenalidomide enhances the immunologic milieu in patients with myeloma by promoting T-cell proliferation and suppressing inhibitory factors, and thereby augmenting responses to a myeloma-specific tumor vaccine.

SUBMITTER: Luptakova K 

PROVIDER: S-EPMC4098790 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications


Lenalidomide is an effective therapeutic agent for multiple myeloma that exhibits immunomodulatory properties including the activation of T and NK cells. The use of lenalidomide to reverse tumor-mediated immune suppression and amplify myeloma-specific immunity is currently being explored. In the present study, we examined the effect of lenalidomide on T-cell activation and its ability to amplify responses to a dendritic cell-based myeloma vaccine. We demonstrate that exposure to lenalidomide in  ...[more]

Similar Datasets

| S-EPMC10104776 | biostudies-literature
| S-EPMC4910703 | biostudies-other
| S-EPMC4968567 | biostudies-literature
| S-EPMC4609232 | biostudies-literature
| S-EPMC5991104 | biostudies-other
| S-EPMC8738460 | biostudies-literature
| S-EPMC5515246 | biostudies-literature
| S-EPMC6010717 | biostudies-literature
2011-09-30 | E-GEOD-31452 | biostudies-arrayexpress
| S-EPMC3744991 | biostudies-literature